Can high molecular weight cytokeratin, CK-903, differentiate benign proliferative breast lesions from atypical ductal hyperplasia and ductal carcinoma in situ?

被引：0
|
作者：
Aziz, M. [1 ]
Troob, S. [1 ]
Simpson, S. [1 ]
Mills, C. [1 ]
Bernik, S. [1 ]
机构：
[1] St Vincents Comprehens Canc Ctr, New York, NY USA
来源：
LABORATORY INVESTIGATION | 2007年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
86
引用
收藏
页码：23A / 23A
页数：1
相关论文
共 24 条
  • [1] Can high molecular weight cytokeratin, CK-903, differentiate benign proliferative breast lesions from atypical ductal hyperplasia and ductal carcinoma in situ?
    Aziz, M.
    Troob, S.
    Simpson, S.
    Mills, C.
    Bernik, S.
    MODERN PATHOLOGY, 2007, 20 : 23A - 23A
  • [2] The Utilities of Estrogen Receptor, Cytokeratin 5/6, and Cytokeratin 903 to Differentiate Between Usual Ductal Hyperplasia, Flat Epithelial Atypia, Atypical Ductal Hyperplasia, Ductal Carcinoma In Situ, and Lobular Carcinoma In Situ
    Wei, Eric
    Dela Cruz, Nestor
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 149 : S30 - S30
  • [3] High molecular weight cytokeratin expression in ductal carcinoma in situ of the breast: a diagnostic pitfall
    Heaton, T.
    Elhag, A.
    Mihai, R.
    Rakha, E.
    Bakhiet, S.
    VIRCHOWS ARCHIV, 2020, 477 : S46 - S47
  • [4] Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ
    Boecker, W
    Moll, R
    Dervan, P
    Buerger, H
    Poremba, C
    Diallo, RI
    Herbst, H
    Schmidt, A
    Lerch, MM
    Buchwalow, IB
    JOURNAL OF PATHOLOGY, 2002, 198 (04): : 458 - 467
  • [5] Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ
    Martinez, Anthony P.
    Cohen, Cynthia
    Hanley, Krisztina Z.
    Li, Xiaoxian
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (07) : 686 - 689
  • [6] Atypical ductal hyperplasia on vacuum-assisted breast biopsy: suspicion for ductal carcinoma in situ can stratify patients at high risk for upgrade
    Allison, Kimberly H.
    Eby, Peter R.
    Kohr, Jennifer
    DeMartini, Wendy B.
    Lehman, Constance D.
    HUMAN PATHOLOGY, 2011, 42 (01) : 41 - 50
  • [7] Prospective Analysis Using a Novel CNN Algorithm to Distinguish Atypical Ductal Hyperplasia From Ductal Carcinoma in Situ in Breast
    Mutasa, Simukayi
    Chang, Peter
    Nemer, John
    Van Sant, Eduardo Pascual
    Sun, Mary
    McIlvride, Alison
    Siddique, Maham
    Ha, Richard
    CLINICAL BREAST CANCER, 2020, 20 (06) : E757 - E760
  • [8] Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: Improved accuracy with directional, vacuum-assisted biopsy
    Burbank, F
    RADIOLOGY, 1997, 202 (03) : 843 - 847
  • [9] p16 as a biomarker to distinguish atypical ductal hyperplasia from ductal carcinoma in situ and to predict breast cancer progression
    Tjoe, Judy
    Brittany, Last
    Yin, Jun
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 53 - 53
  • [10] Papillary lesions of the breast with and without atypical ductal hyperplasia - Can we accurately predict benign behavior from core needle biopsy?
    Agoff, SN
    Lawton, TJ
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (03) : 440 - 443
123